Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 9/20 | 0.57 |
| ▸ | CRBN | Q96SW2 | 9/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | HTR3A | P46098 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | KHK | P50053 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | PRKDC | P78527 | 2/20 | 0.39 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.37 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29402675 | 1.00 | DDB1 (0.57) | DDB1CRBNTDP1SLC6A2SLC6A4 | |
| SCHEMBL30273533 | 0.85 | DDB1 (0.60) | DDB1CRBNHRH3KHKPIK3CA | |
| SCHEMBL25036127 | 0.85 | DDB1 (0.60) | DDB1CRBNHRH3KHKPIK3CA | |
| SCHEMBL24269093 | 0.84 | CRBN (0.51) | DDB1CRBNSLC6A4ITGB3ITGA2B | |
| SCHEMBL31553873 | 0.84 | CRBN (0.61) | DDB1CRBNIKZF3 | |
| SCHEMBL31282331 | 0.83 | DDB1 (0.52) | DDB1CRBNHRH3PIK3CAPRKDC | |
| SCHEMBL21760046 | 0.83 | CRBN (0.69) | DDB1CRBNIKZF3 | |
| SCHEMBL22526122 | 0.83 | CRBN (0.69) | DDB1CRBNIKZF3 | |
| SCHEMBL24269441 | 0.82 | DDB1 (0.51) | DDB1CRBNPIK3CAPRKDC | |
| SCHEMBL21071373 | 0.82 | DDB1 (0.60) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240100170-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2024-03-28 | — | — | US | disclosed |
| CN-116507333-A | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2022042707-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100170-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CREBBP, EP300, CREB1 | DDB1 33/4885CRBN 91/4885TDP1 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.